Chugai Pharmaceutical Co., Ltd.
Notice on the Finalization of Details for Share Acquisition Accompanying the Introduction of the Trust-Type Stock Compensation Plan
Chugai Pharmaceutical will acquire ordinary shares totaling JPY 4,360 million from the market between May 1 and the end of May 2026, in conjunction with the introduction of a trust-type stock compensation plan.
Key Figures
- Director Compensation BIP Trust Fund Amount: JPY 1,860 million (including subsidiary directors)
- Stock Grant ESOP Trust Fund Amount: JPY 2,500 million (including subsidiary employees)
- Share Acquisition Period: 2026-05-01 to End of May 2026
AI要約
Overview of the Introduction of the Trust-Type Stock Compensation Plan
At the Board of Directors meeting held on April 24, 2026, Chugai Pharmaceutical Co., Ltd. resolved the scale and timing of acquiring the Company's ordinary shares in connection with the trust-type stock compensation plan. This plan aims to provide incentives to directors, subsidiary directors, employees, and others. The trust agreement will be in effect from April 27, 2026, until the end of May 2030. Shares will be acquired from the market and voting rights will not be exercised.
Impact on Shareholders and Future Schedule
The total acquisition amount is JPY 1,860 million for the Director Compensation BIP Trust and JPY 2,500 million for the Stock Grant ESOP Trust, totaling JPY 4,360 million. Share acquisition is scheduled to be conducted between May 1 and the end of May 2026. Accordingly, these shares will be granted to directors and employees through the trust, with no impact on shareholders' voting rights. The plan has already been approved at the Annual General Meeting of Shareholders held on March 26, 2026.
Chugai Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
